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Abstract
Background: Chronic Lymphocytic Leukemia (CLL) leads to progressive accumulation of lymphocytes in the blood, bone
marrow, and lymphatic tissues. Previous findings have suggested that the mtDNA could play an important role in CLL.
Methodology/Principal Findings: The mitochondrial DNA (mtDNA) control-region was analyzed in lymphocyte cell DNA
extracts and compared with their granulocyte counterpart extract of 146 patients suffering from B-Cell CLL; B-CLL (all
recruited from the Basque country). Major efforts were undertaken to rule out methodological artefacts that would render a
high false positive rate for mtDNA instabilities and thus lead to erroneous interpretation of sequence instabilities. Only
twenty instabilities were finally confirmed, most of them affecting the homopolymeric stretch located in the second
hypervariable segment (HVS-II) around position 310, which is well known to constitute an extreme mutational hotspot of
length polymorphism, as these mutations are frequently observed in the general human population. A critical revision of
the findings in previous studies indicates a lack of proper methodological standards, which eventually led to an
overinterpretation of the role of the mtDNA in CLL tumorigenesis.
Conclusions/Significance: Our results suggest that mtDNA instability is not the primary causal factor in B-CLL. A secondary
role of mtDNA mutations cannot be fully ruled out under the hypothesis that the progressive accumulation of mtDNA
instabilities could finally contribute to the tumoral process. Recommendations are given that would help to minimize
erroneous interpretation of sequencing results in mtDNA studies in tumorigenesis.
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Introduction
Chronic Lymphocytic Leukemia (CLL) becomes manifest in
progressive accumulation of lymphocytes in the blood, bone
marrow, and lymphatic tissues [1]. B-CLL is the most frequent
form of leukemia in Western countries and represents 30% of all
leukemic cases [2]. Studies on ethnic distribution of CLL in the
world have shown considerable variation [3], Thus for instance,
according to the American Cancer Society (http://www.cancer.
org), about 15,490 new cases of CLL will be diagnosed in the
United States during 2009, and about 4,390 people will die of
CLL in this country during this year. For patients with progressing
CLL, treatment with conventional doses of chemotherapy is not
curative; selected patients treated with allogeneic stem cell
transplantation achieved prolonged disease-free survival [4,5].
The median survival for all patients ranges from 8 to 12 years in
older trials [6]. CLL occurs primarily in middle-aged and elderly
adults, with increasing frequency in successive decades of life. The
clinical course of this disease progresses from an indolent
lymphocytosis without other evident disease to one of generalized
lymphatic enlargement with concomitant pancytopenia. Compli-
cations of pancytopenia, including haemorrhage and infection,
represent a major cause of death in these patients [7]. Prognostic
factors that may help predict clinical outcome include cytogenetic
subgroup, immunoglobulin mutational status, ZAP-70, and CD38
(see for instance [1]). Staging is useful in CLL to predict prognosis
and also to stratify patients to achieve comparisons for interpreting
specific treatment results. Anemia and thrombocytopenia are the
major adverse prognostic variables. Although CLL has no
standard staging system, the most common ones are the Rai
staging system and the Binet classification [1,8]. New prognostic
markers have been proposed to the clinician and investigator [9].
The potential role of the mtDNA genome in CLL was first
approached by Carew et al. [10] analyzing a sample of 20 patients.
According to these authors, chemotherapy with DNA-damaging
agents could cause mtDNA mutations in primary leukemia cells,
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which often exist in heteroplasmic condition. These findings were
later put into question by Meierhofer et al. [11], who showed that
platelet transfusion can mimic somatic mtDNA mutations. He et
al. [12] sequenced the entire mtDNA from both normal tissue
(buccal epithelial cells) and cells extracted from bone marrow in 24
patients with adult-onset leukemia. They reported mtDNA
mutations in nine tumoral mtDNAs (one mutation per patient)
and, in particular, inferred pathogenic implications of the
mutation A15296G in leukemia. Grist et al. [13] analyzed mtDNA
mutations in 22 patients with acute myeloid leukemia (AML) and
26 patients with acute lymphoblastic leukemia (ALL). The authors
found (multiple) mtDNA control-region mutations in 36% of the
AML patients and in 58% of the ALL patients, but the sequence
information was not provided for closer examination. It was
pointed out by the authors that most of the mutations tended to
appear at hotspots: ‘‘several hotspots were at sites of poly C tracts, but there
was no single-sequence motif which seemed to be associated with mutations’’
[13]. In a comprehensive review, Gattermann [14] analyzed the
implications of mtDNA mutations in leukemogenesis. Recently,
Yao et al. [15] studied mtDNA sequence variation in more than
3,500 single normal cells and individual blasts from 18 patients
with leukemia and 10 healthy donors. Further they found that the
somatic mutation process in leukemia is complex and generally
leads to diverse levels of genetic alterations. These authors also
observed that the somatic mutation events in single hematopoietic
cells are prone to occur at well-characterized mutation hot spots,
thus corroborating the results previously obtained in tumors of the
central nervous system [16].
He et al. [12] conducted the first mtDNA study that aimed at
comparing mtDNA extracted from leukemic cells with mtDNA
extracted from buccal mucosa cells from the same patient,
observing that 40% of their patients bear somatic point mutations
in their mtDNAs. Other studies[17,18] compared mtDNA from
clonal bone marrow disorders with mtDNA obtained from healthy
individuals; as advanced by Gattermann [14], these studies
however may be futile since these comparisons just reflect the
biological differences that exist between mtDNA lineages within or
between human population groups (see also [19]). It has been
claimed in numerous studies that the mtDNA molecule is in
general prone to instability in tumorigenesis, and even hypothe-
sized that mtDNA genome instability could play some active role
during the development of the tumor in several types of cancer.
Most of these studies, however, are most problematic in view of the
patterns of recorded mtDNA alterations between putatively
matched tissues, which are more akin to the result of sample
mixing [19,20,21]. This prompted us to take a closer look at the
previous mtDNA sequencing results in patients with CLL, AML,
and ALL (especially those from Carew et al. [10]) in order to
exhibit patterns that would clearly point to artefacts or other
shortcomings.
To shed more light on the debatable issue of mtDNA alterations
in leukemia we analyzed mtDNA instability in a large number of
B-CLL patients from the same geographic area (Basque country)
under strict laboratory conditions. Since previous studies always
found alterations in the control-region, we sequenced the entire
mtDNA control-region in lymphocytes obtained from blood
samples of the B-CLL patients. Since the myeloid line and, in
particular, the granulocytes should not be directly affected in B-
CLL patients, these cells were used as the corresponding control
samples for instability in the lymphoid line of each patient. In
contrast to previous attempts, our design involved the comparison
of two different cell lines that have very recent common cell
ancestors (the colony deriving from the pluri-potent stem cells) in
order to maximally rule out the effect of tissue-mediated
instabilities. Such instabilities exist even when comparing different
fragments of hairs from the same (healthy) individual [22,23].
Materials and Methods
Ethical Statement
The study was conducted according to the Spanish Law for
Biomedical Research (Law 14/2007- 3 of July) and complied with
the Declaration of Helsinki. The study and the use of archive
samples for this project was approved by the Ethics Committee of
the University of Santiago de Compostela where the study was
carried out. Written informed consent was obtained for all
patients. All the samples were collected anonymously.
Sample Collection and DNA Extraction
A total of 146 blood samples from patients diagnosed of B-CLL
were collected (2–4 ml) by venous puncture using EDTA as
anticoagulant. The patients belong to the sanitary area of the
Hospital de Tagorritxu and Basurto in the Basque country.
Written informed consent was obtained for all individuals.
Granulocyte and lymphocyte cells were separated using a
gradient Ficoll-Paque Plus (Amhersham Biosciences) using man-
ufacture protocols (see also Carew et al. [10] for a similar
approach). According to manufacture instructions, we did not
remove excess Ficoll-Paque PLUS in order to minimize contam-
ination of the lymphocytes fraction with granulocytes. Platelets
were removed as indicated in those instructions. These protocols
minimize the presence of non-lymphocyte cells in the lymphocyte
fraction and lead to the purification of the lymphoid extraction for
the presence of lymphocytes.
We also recovered the granulocyte cell fraction. According to
manufacture instructions, the efficiency of the separation is as
follows: lymphocytes ,95% of cells present in fraction are
mononucleocytes, and ,60% recovery of lymphocytes from the
original blood sample. There are other cells in the extract: ,3%
granulocytes, ,3.5% erythrocytes, and ,0.5% of total platelets in
the original blood sample. By using washing protocols, we
intended to further improve the cell separation and purification
of the lymphocyte and granulocyte cell fractions. Note also that
standard sequencing protocols cannot detect the presence of a
minor non-lymphoid cell component in the lymphocyte extract if
this component is below ,10% of the mixture. In any case, the
presence of such cell mixture would not mask the mutational
difference (if any) between both cell lines; this difference would be
generally detected as a heteroplasmic-like pattern.
After the two fractions were obtained, we extracted the DNA
using a standard phenol-chloroform protocol [24]; quantification
was performed using GeneQuant Pro (Pharmacia), which showed
variable concentrations varying between 10 to 100 ng/ml.
PCR Amplification and Automatic Sequencing of the
mtDNA Control-Region
The PCR was performed in 22 ml of reaction mixture
containing 50 mM of each dNTP (200 mM of GeneAmpH
10 mM dNTP Mix with dTTP, Applied Biosystems [AB], Foster
City, CA, USA), 2,5U Taq DNA Polymerase, recombinant
(Invitrogen, Carlsbad, CA, USA), 1X PCR Buffer, 1,5 mM of
Magnesium Chloride, 016 mM of BSA, 0,2 mM of each primer
forward and reverse (15997L and 017H for HVS-I, and 16555L
and 599H for HVS-II; Table 1), water-up to 22 ml and 3 ml sample
template. PCR amplification was carried out in a thermocycler
GenAmp PCR System 9700 (AB) with the following conditions:
one cycle of 95uC for 1 minute; then 35 cycles of 95uC for 10
seconds, 55uC for 30 seconds and 72uC for 30 seconds, and ending
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15uC for 10 minutes. For those samples showing insertions at 573,
we additionally used the amplification pair of primer 332L [15]
and primer 901H [25] in order to obtain forward and reverse
reading (Table 1).
After this reaction, PCR products and negative controls were
checked in polyacrylamide gel and visualized with silver staining.
Then PCR products were purified to remove excess of primers
and un-incorporated dNTPs in MultiScreenHPCRm96 plates
(Millipore, Bedford, MA, USA) according to the manufacturer
protocol.
Sequencing reaction was performed in 11.5 ml of reaction
mixture, containing 2.5 ml of sequencing buffer (5X), 0.5 ml of
BigDye Terminator v3.1 Cycle Sequencing Kit (AB), 1 ml of the
corresponding primer (final concentration was 1 mM), 3 ml of the
purified PCR product and water up to 11.5 ml. Sequencing
reaction was carried out in a thermocycler GenAmp PCR
System 9700 (AB) with one cycle of 96uC for 3 minutes and then
25 cycles of 96uC for 30 seconds, 50uC for 15 seconds and 60uC
for 4 minutes or was carried out in a 9800 Fast Thermal Cycler
(AB) with one cycle of 96uC for 1 minute then 25 cycles of
96uC for 10 seconds, 50uC for 5 seconds and 60uC for 1 minute.
To obtain ‘clean’ electropherograms, the sequencing product
was doubly purified, first using MontageTM SEQ96 Sequencing
Reaction Cleanup Kit (Millipore) according to manufacturer
protocols, followed by purification with SephadexTM G-10
(Amersham Biosciences, Uppsala, Sweden), the latter also
according to manufacturer protocol. MtDNA automatic se-
quencing was carried out in a capillary electrophoresis ABI3730
(AB). Each pair of samples showing differences between
granulocytes and lymphocytes were sequenced in both forward
and reverse directions. In order to obtain clear pattern of
instability or simply to allow the reading of length variability,
additional ad hoc primers were used (the full list of primers is
given in Table 1).
All instabilities found at this stage were first rechecked in the
same laboratory through all the steps involving PCR amplification
and sequencing in forward and reverse direction for both the
granulocytes and the lymphocytes counterparts by using a slightly
different protocol which allows to minimize potential technical
artefacts. The PCR was performed in 10 ml of reaction mix,
containing 4 ml of Taq PCR Master Mix (Qiagen, Hilden,
Germany), 0.5 ml 1 mM of each primer, 1 ml sample template
and 4 ml of water. This PCR was carried out in a thermocycler
GenAmp PCR System 9700 (AB) with one cycle of 95uC for 15
minutes and then 35 cycles of 94uC for 30 seconds, 58uC for 90
seconds and 72uC for 90 seconds with a full extension cycle of
72uC for 10 minutes. The PCR product was purified with
ExoSAP-IT (Amersham Biosciences): 2.15 ml of PCR product was
incubated with 0.85 ml ExoSAP-IT for 20 min at 37uC followed
by 15 min at 80uC for enzyme inactivation. The next steps (e.g.
sequencing, purification) were carried out using the protocol
described above.
Assessing Sequence Quality
The SeqScape v.2.5 (AB) was set up to automatically detect the
presence of heteroplasmic-like patterns involving at least 15% of
the signal for the minor variant; in addition, all the electrophe-
rograms were inspected visually. In order to avoid erroneous
interpretation of seeming DNA instabilities [19] we have followed
a phylogenetic framework [19,26,27,28] that allowed us to detect
some errors committed during the analytical and documentation
process. Indeed, the analysis of DNA (usually through automatic
sequencing) has always been prone to errors of different nature
[26,27,29,30,31,32,33,34,35].
All sequence instabilities detected in our set of samples were
finally confirmed by sequencing the forward and reverse strains
and replicated in a different laboratory by a different analyst. The
laboratory where the replication was carried out was not informed
about the sequence profiles expected for the DNA samples in
order to rule out any bias in reading and interpreting sequencing
electropherograms. Control samples (those without any apparent
instability) were also submitted to the second lab as well as samples
showing seeming instabilities in the forward but not replicated in
the reverse sequencing. All the probable instabilities observed in
the first laboratory were confirmed in the second laboratory. The
sequencing results obtained for all the samples are presented in
Data S1.
Table 1. Set the primers used for PCR amplification and sequencing.
mtDNA segment PCR primer (59 to 39) Sequencing primers (59 to 39)
HVS-I (16024-16569) 15997L CACCATTAGCACCCAAAGCT 15997L CACCATTAGCACCCAAAGCT
– – 16254L CACATCAACTGCAACTCCAAA
– – 16236H CTTTGGAGTTGCAGTTGATG
– – 16401H TGATTTCACGGAGGATGGTG
– – 16450H CAAGTGTTATGGGCCCGGAGC
– – 16380L TCAGATAGGGGTCCCTTGAC
017H CCCGTGAGTGGTTAATAGGGT 017H CCCGTGAGTGGTTAATAGGGT
HVS-II (1-578) 16555L CCCACACGTTCCCCTTAAAT 16555L CCCACACGTTCCCCTTAAAT
– – 172L ATTATTTATCGCACCTACGT
– – 285H GGGGTTTGGTGGAAATTTTTTG
332L CCCGCTTCTGGCCACAGCAC 332L CCCGCTTCTGGCCACAGCAC
– – 370L CCCTAACACCAGCCTAACCA
– – 408H CTGTTAAAAGTGCATACCGCCA
599H TTGAGGAGGTAAGCTACATA 599H TTGAGGAGGTAAGCTACATA
901H ACTTGGGTTAATCGTGTGACC 901H ACTTGGGTTAATCGTGTGACC
doi:10.1371/journal.pone.0007902.t001
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Identification of the Same Donor for Each Pair of
Lymphocyte and Granulocyte Samples
For all those samples showing instability-like patterns we
genotyped a set of microsatellites in the lymphocyte fraction and
their counterpart granulocytes. This (along with sharing the same
mtDNA profile) allowed us to corroborate a common biological
source for these pairs of samples and therefore practically rule out
potential sample mix-up. We have followed the protocols of the
Instituto de Medicina Legal of the Universidad de Santiago de
Compostela. The following STR autosomal markers were analyzed
using PowerPlexH 16 System (Promega; Madison, USA): D21S11,
D3S1358, PENTA-E, D16S539, CSF1PO, FGA, PENTA-D,
TPOX, TH01, vWA, D8S1179, D18S51, D5S818, D7S820,
D13S317, and amelogenin. Samples were additionally genotyping
using PowerPlexH which contains the same STRs as PowerPlexH
(with the exception of PENTA-D and PENTA-E) but has in
addition the STR markers D19S433 and D2S1338.
Phylogenetic Analysis and Database Comparisons
Polymorphisms are referred with respect to the revised Cam-
bridge Reference Sequence (rCRS [36]). Haplogroup classification
was carried out alter alia according to ref. [37,38,39,40,41,42,43,44],
and using the most up to date mtDNA tree from http://www.
phylotree.org/. A worldwide mtDNA database of control-region
sequences published in the literature and/or Genbank was used for
searching mtDNA profiles; this database also contains Basque and
other Iberian profiles (e.g. [45,46,47,48]).
Statistical Analysis
Pearson’s Chi-squared test with Yates’ continuity correction was
computed in order to test for possible association between clinical-
pathological variants (Table 2) and the amount of instabilities
Table 2. Clinico-pathological characteristics of patients with
B-CLL.
Age (years)
range 33 to 92
mean 69
Gender
Male ,57%
Female ,43%
Origin
Araba (Basque Country, Spain) ,90%
Gupuzkoa (Basque Country; Spain) ,1%
Burgos (Castilla; North-central Spain) ,1%
Transplant
none 100%
Inmuno-phenotype
19+ and 5+ ,95%
FMC7- ,95%
79b- ,92%
23+ ,91%
38- ,85%
10- ,76%
22- ,66%
k+ ,44%
k- ,33%
a- ,29%
a+ ,26%
22+ ,25%
38+ ,8%
79b+ ,4%
CD38
.30% ,6%
,30% ,94%
Serological markers
LDH high ,14%
LDH normal ,86%
B2MG high ,45%
B2MG normal ,55%
Tissue morphology
typical ,82%
atypical ,18%
Survival
alive ,92%
exitus ,8%
RAI classification
stage 0 ,54%
stage I ,31%
stage II ,6%
stage III ,1%
stage IV ,8%
Binet staging
stage A ,88%
stage B ,2%
Age (years)
stage C ,10%
Adenopaties
yes ,32%
no ,68%
Marrow infiltration
non-diffuse ,87%
diffuse ,13%
Electromagnetic
radiation
yes ,7%
no ,83%
Treatment
none ,68%
Leukeran ,18%
Ciclosfosfamida ,9%
Fluradabina ,8%
Chop ,8%
Clorambucil ,6%
anti CD20 ,6%
Prednisona ,4%
doi:10.1371/journal.pone.0007902.t002
Table 2. Cont.
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found and haplogroup status. In order to adjust P-values for
multiple tests, we applied Bonferroni correction and the procedure
[49] to control the False Discovery Rate at the level of a= 0.05:
(i) for m tests, the P-values are ranked in ascending order
P(1)#P(2)#…#P(m), (ii) denote by H(i) the null hypothesis
corresponding to P(i); let k be the largest i for which
P(i)ƒ
a
m
i
and (iii) all null hypotheses H(1) … H(k) are rejected.
Statistical evaluation of the common biological source for pairs of
tumor/non-tumor samples showing mtDNA instabilities has been
carried out according to standard forensic conventions for sample
identification. Thus, the software Familias 1.81 [50] was used to
compute the likelihood ratio (LR) that considers the probability of
the evidence given two alternative hypotheses: the samples came
from the same donor versus the samples came from different donors).
LR was in all the cases higher than 1013 (Data S2).
Results
Reassessment of the Data from Carew et al. (2003)
Carew et al. [10] analyzed four mtDNA fragments from
peripheral blood samples from 20 patients with B-CLL (10
untreated and 10 treated with chemotherapy). According to the
authors, their results ‘‘revealed that primary CLL cells from patients with
prior chemotherapy has a significantly higher frequency of heteroplasmic
mutations than did those from untreated patients’’ [10]. Note however, that
no attempt was made to determine the effect of chemotherapy in
one and the same patient, and no attempt was made to distinguish
mutations in the blood fraction (lymphocytes, in particular) from
germline mutations. Therefore, from the outset, the design of the
experiments is not really appropriate for understanding the role of
mtDNA mutations in leukemia since there is no way to know
whether the differences observed between treated versus untreated
patients were due to normal variation between individuals rather
than a higher rate of instability in treated patients.
The mtDNA regions that could be analyzed for mutations are
the amplified fragments minus primer locations, i.e. 35–464
(covering the second hypervariable segment, HVS-II), 3324–3806,
7665–8296, 8560–9039, 11424–11905, and 15281–15752. The
obtained sequence fragments were apparently compared to
some version of the Cambridge Reference Sequence (CRS) but
obviously not to the sequence NC_18007.4 as asserted by Carew
et al. (2003), which e.g. bears the changes A73G, C150T, T195C,
A263G, 309+C, 315+C, and T408A relative to the rCRS. The
rCRS is a member of haplogroup H2a2, the root of which is
distinguished from rCRS by the four changes A263G, 315+C,
A8860G, and A15326G [51]. These changes should have been
observed in almost all mtDNA sequences under study. However,
the latter two mutations were nowhere recorded in those tables
[10] and, in addition, the former two are lacking in patients UT7
and UT8.
The authors seem to have then interpreted their sequencing
results under the wrong premise that the amount of differences to
the rCRS could be indicative of cancer [19]. However, the
worldwide phylogeny clearly shows that the rCRS is just one
particular mtDNA lineage typically differing from other lineages
by dozens of changes. The obtained sequencing results can be
compared, one by one, to the entire database of complete mtDNA
sequences. Leaving heteroplasmic changes aside for the moment,
all 20 sequences except one testify to lineages of West Eurasian
(and European, in particular) ancestry.
The mtDNA lineages of patients T1, T4, T5, T9, T10, UT1, UT2,
and UT5 may all belong to haplogroup H (or at least to the larger
haplogroup HV). In particular, T1, T5, and T9 bear the mutation
C456T characteristic of haplogroup H5. Moreover, the three
changes T195C, A257G (which is a quite rare event), and 309+C
found in patient UT1 are shared with a particular lineage from
haplogroup H1 (GenBank accession number EF177411 [52]).
Patients T2 and T3 bear mtDNA lineages belonging to a specific
branch of haplogroup K1a1a that have C114T; evidently, A73G and
A263G were overlooked in Patient T3. Patients UT7 and UT8 have
haplogroup K1a4a1 lineages, for which A263G and 315+C were not
recorded; the nucleotide information for UT7 in column ‘‘Change’’
of the table is mis-documented. Patients T6, T7, and T10 have
haplogroup U lineages, which cannot be further specified except for
excluding subhaplogroup status K, U1b, U2e, U3, U499, U5b, and
U6, so that U5a status would be most probable. In fact, mutation
T15565C has been detected sporadically in some haplogroups,
including haplogroup U5a (http://freepages.genealogy.rootsweb.
ancestry.com/,ncscotts/mtDNA/GenBank%20Mutation%20Lists/
hg%20U/mtDNA_hg_U_Mutation_Distribution.htm). The mtDNA
lineage of patient UT9 is a J1c1 lineage, whereas the UT3 lineage is a
specific J1c lineage not belonging to J1c1 but instead sharing the entire
motif from the region 35–464 plus the infrequent mutation G8865A
with the J1c lineage of GenBank accession number EU573192
(submitted by the company ‘Family Tree DNA’); the lack of G11719A
likely represents an oversight. The mtDNA of patient UT6 is of non-
European ancestry; this profile belongs to the East Asian haplogroup
F3 as inferred from the rare combination 249del and A3434G.
Finally, the reported mtDNA variation of the patients T8 and
UT4 is of mosaic nature. Namely, all mutations except for 309+C
in region 35–464 match sequence no. 19 from ref. [41], which in
particular encompass the rare mutation pair T279C, C285T that
(in combination) is absolutely specific to haplogroup U1b. The
coding-region variation, however, perfectly matches haplogroup
K1a1b1 members. The most parsimonious explanation for this
puzzling pattern is sample mix-up resulting in an inadvertent
exchange of the amplicon for the control-region fragment.
Similarly, patient T8 is assigned a mixed variation pattern, where
the control-region fragment unambiguously indicates a hap-
logroup I lineage and the coding-region fragments point to
haplogroup U (A11467G) instead of haplogroup I (with expected
mutation G8251A).
The heteroplasmic variation is so immense and bizarre that it
cannot reflect natural variation: most seeming heteroplasmies
cluster in quite narrow stretches of the amplified fragments,
especially in 3356–3410. Such patterns are indicative of artefacts
termed phantom mutations. The amount of DNA and the number
of PCR cycles were in fact too high, which together with a low
temperature for the primers would invite all kinds of artefacts [53].
Similarly inadvertent amplification and sequencing conditions
(following a forensic protocol that was widely used at the time) led
to an excess of seeming heteroplasmies in hair roots [54], which
was later admitted and corrected by the authors [55].
In summary, nearly all the heteroplasmic variation in
Tables 1 and 2 of Carew et al. [10] is very likely induced by
suboptimal amplification and sequencing protocols and thus
artefactual. In contrast, the reported homoplasmic variation
does not exhibit any excess or unexpected mutations: by and
large, it matches the natural variation in the general popula-
tion. A few mutations were actually not recorded, either by
systematic employment of a wrong reference sequence or
through oversight. Moreover, two samples were contaminated
or confused at the amplification steps as testified by two clear-cut
cases of artificial recombination.
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Apparent Instabilities and Data Quality Assessment
Heteroplasmic-like patterns frequently show up in the electro-
pherograms as a result of sequence background noise. Some of these
artefacts occur within the same sequencing plate and are not
reproducible when replicating the sequencing in different plates. For
instance, Data S3 shows an example affecting position 220 in HVS-
II in one plate that was not replicated in a second sequencing round
carried out in a different plate. Some of these unspecific artefacts
appear as arrays of positions (e.g. 16105-16305-16310). Many of
these spurious changes did not constitute typical phantom mutations
that would occur at well-known sites [29,56]. We have also observed
that several positions appear to be instable (with heteroplasmic-like
patterns) in forward but not in reverse sequence electropherograms
or vice versa. With single-strand reading there is a high risk of taking
these artefacts as face value of real mtDNA instability.
We also detected a case of sample mix-up due to an erroneous
labelling of samples: LL79 was initially labelled as LL80 and vice versa.
Since these two samples belong to two different haplogroups (with
different sets of diagnostic motifs in the control-region), the error could
be easily detected: the mtDNA profile of 79LG was C16111T-
A16220C-T16362C-T16519C-A263G-309+C-315+C (belonging to
haplogroup HV), while the profile of its seeming counterpart 79LL
(80LL in reality) was C16069T-T16126C-G16145A-T16172C-
T16231C-C16261T-A73G-C150T-T152C-T195C-A215G-A263G-
C295T-310+T-315+C-T319C-T489C-G513A (haplogroup J2a1a1).
This kind of ‘artefactual instability’ due to sample mixing could
go unnoticed in case the two samples would share very similar
variation (e.g. when they belong to the same narrow sub-
haplogroup). Therefore, the best way to determine whether both
samples belong to the same biological source or not is to genotype
a set of autosomal markers as was carried out in the present study.
Confirmed Mutation Instabilities in B-CLL Patients
We considered confirmed mtDNA instabilities those sequence
patterns that could be replicated in the first round of sequencing
analysis in both forward and reverse strands, and additionally in
an independent laboratory by a different analyst. Moreover,
granulocyte and the counterpart lymphocyte mtDNA profiles
matched phylogenetically in all the cases. Identification analysis
carried out by means of STR autosomal profiling (as commonly
exercised in the forensic field; ), further corroborated the common
biological source of each pair of samples (lymphocytes/granulo-
cytes) taken from the patients analyzed in the present study.
We have detected instability-like patterns in a total of 20 patients
(Table 3). Data S1 shows the full list of haplotypes obtained for the
146 patients analyzed in the present study. Figure 1 shows the
electropherogam of a single example of instability whereas Data S4
shows the electropherograms for the full set of instabilities observed.
Most of the instabilities (76%) appear associated with the
homopolymeric C-stretch located in HVS-II around position 310.
These instabilities are well known in forensic science. Further
known hotspots affected by instabilities were positions 152 and
16093, the dinucleotide variation between 514 and 523, as well as
the C-homopolymeric tract around position 570.
Most haplogroups characteristic of West Eurasia were present in
our sample of B-CLL. The instabilities observed did not cluster in
any particular haplogroup.
Testing for statistical association between haplogroup and
clinical-pathological variants and the incidence of mtDNA
instabilities
The best P-value value for the potential association between the
amount of instabilities and the haplogroup status was found to be
for haplogroup H, (P-value = 0.0024; Chi-square). Adjustment for
multiple testing either using Bonferroni or FDR test (adjusted
a= 0.0022 for both tests) indicates a lack of statistical association
between the presence of instabilities with the HG status and the
clinical-pathological variants (Table 2).
Discussion
Our experimental design explored the accumulation of mutations
in two different cell lines that are biologically very closely related:
both kinds of cell lines have their origin in single pluri-potent stem
cells, so that the differences that could arise in the mtDNA of these
two cells would be due mainly to the tumor condition of the
lymphocyte line and not predominantly to somatic differences that
arose during the differentiation process of these cell lines. We have
detected a total of twenty cases carrying mtDNA instabilities, most
of them affecting well-known hotspots in the mtDNA genome. This
lends additional support to the hypothesis formulated in Vega et al.
[16]; briefly, mtDNA instability occurs predominantly at natural
hotspots and is at least in a first stage neutral to DNA function. We
did not find any mtDNA instability that would follow a pathway in
the mtDNA phylogeny and mimic a haplogroup motif (contra
Linnartz et al. [57]).
Thus, an important amount of our analytical effort was devoted
to the sequence quality and assessment of mtDNA instability. We
only consider the existence of instability if it is confirmed in the
forward, the reverse strands, in different DNA amplicons, and
replicated in different laboratories. These aspects are particularly
important in tumor studies since the use of relaxed criteria to assess
instability can alter significantly results and conclusions. Despite
the precautions for avoiding contamination, we detected an
instance of sample mix-up that could have led to an erroneous
interpretation of multiple instabilities (see above). Re-analysis of
these samples uncovered the source of the error and fully ruled out
the apparent evidence of instability.
In conclusion, instabilities observed in B-CLL patients seem to
be neutral to DNA function and likely do not contribute to the
tumor development.
We here advance some recommendations that would help to
minimize erroneous interpretation of sequencing results in
mtDNA studies in tumorigenesis:
N No instance of seeming heteroplasmy should be interpreted as
real instability unless it is fully confirmed with forward and
reverse sequencing.
N It is highly recommended to replicate positive results of
instabilities in a second laboratory.
N Samples showing instability patterns (e.g. tumor and its
counterpart ‘healthy’ control sample) should be genotyped
for a set of autosomal markers (e.g. microsatellites) in order to
preclude erroneous assignment of samples to an individual.
N Reverse and forward electropherograms for the instabilities
found should be presented in manuscripts.
N Full mtDNA sequence results should be presented in the text
[16] for the whole set of individuals analyzed rather than mere
summary statistics that would only report the number of
instabilities observed at individual positions [19].
Supporting Information
Data S1 MtDNA sequencing results for the entire control-region
of the mtDNA genome in 146 pairs of samples of granulocytes (HG
or LG) and lymphocytes (HL or LL) obtained from B-CLL patients.
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Found at: doi:10.1371/journal.pone.0007902.s001 (0.05 MB
XLS)
Data S2 LR values for the identification of the common
biological source for those pairs of tumor/non-tumor samples
showing mtDNA instabilities.
Found at: doi:10.1371/journal.pone.0007902.s002 (0.02 MB
XLS)
Data S3 Sequence electropherograms of the mtDNA hetero-
plasmic-like pattern at position 220 in HVS-II showing up as
seemingly heteroplasmic in one plate but not replicated in a second
round of sequencing analysis carried out in a different plate.
Found at: doi:10.1371/journal.pone.0007902.s003 (0.07 MB
DOC)
Data S4 Full set of sequence electropherograms showing the
mtDNA instabilities detected in the present study. For each pairs
of samples (indicated right below each tetrad of electropherograms
together with the description of the instability observed), we
indicate the forward (top pair electropherogram) and the reverse
(bottom pair of electropherograms) sequences.
Found at: doi:10.1371/journal.pone.0007902.s004 (2.22 MB
DOC)
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Table 3. Summary of the mutational differences found between granulocytes (G) and their counterpart lymphocytes (L).
NUCLEOTIDE POSITION REGION CHANGE (with respect to rCRS) Frequency Cell type
16093 MT-HV1 TRC 1 (homoplasmic) G
TRC.T 1 (heteroplasmic) L
TRT.C 1 (heteroplasmic) G
TRT&C 1 (heteroplasmic) L
16224 MT-HV1 TRC 1 (homoplasmic) G
TRC.T 1 (heteroplasmic) L
16235 MT-HV1 ARG 1 (homoplasmic) L
ARG.A 1 (heteroplasmic) G
16270 MT-HV1 CRT&C 1 (heteroplasmic) G
CRT.C 1 (heteroplasmic) L
16302 MT-HV1 ARA = G 1 (heteroplasmic) G
ARG.A 1 (heteroplasmic) L
16362 MT-HV1 TRT.C 1 (heteroplasmic) G
TRC.T 1 (heteroplasmic) L
73 MT-HV2 ARG 1 (homoplasmic) L
ARG&A 1 (heteroplasmic) G
152 MT-HV2, MT-OHR TRT&C 1 (heteroplamic) L
TRT.C 2 (heteroplasmic) G
TRT = C 1 (heteroplasmic) L
228 MT-HV2, MT-OHR, MT-CSB1 GRA 1 (homoplasmic) L
GRA&G 1 (heteroplasmic) G
303-309 MT-HV2, MT-OHR, MT-CSB2 7CR8C 1 (homoplasmic) L
7CR8C.7C 2 (heteroplasmic) G
7CR8C = 9C 3 (heteroplasmic) G and L
7CR8C = 9C.7C 1 (heteroplasmic) G
7CR8C.9C 4 (heteroplasmic) G and L
7CR8C,9C 2 (heteroplasmic) L
7CR9C.10C 1 (heteroplasmic) G
7CR9C,10C 1 (heteroplasmic) L
514-523 (CA)5R(CA)5.(CA)4 1 (heteroplasmic) G
568-573 6CR7C 1 (homoplasmic) L
6CR8C.6C 1 (heteroplasmic) G
6CR9C 1 (heteroplasmic) G
6CR10C 1 (homoplasmic) L
6CR10C.9C 1 (heteroplasmic) L
doi:10.1371/journal.pone.0007902.t003
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Figure 1. Example of mtDNA instability observed at position 152 in HVS-II; forward in granulocytes (a) and lymphocytes (b) and the
reverse patterns in granulocytes (c) and lymphocytes (d).
doi:10.1371/journal.pone.0007902.g001
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